News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,579 Results
Type
Article (42393)
Company Profile (464)
Press Release (660722)
Section
Business (208721)
Career Advice (2006)
Deals (36025)
Drug Delivery (94)
Drug Development (84090)
Employer Resources (169)
FDA (16444)
Job Trends (15070)
News (353353)
Policy (33105)
Tag
Academia (2635)
Alliances (50778)
Alzheimer's disease (1278)
Approvals (16366)
Artificial intelligence (139)
Bankruptcy (362)
Best Places to Work (11753)
Biotechnology (349)
Breast cancer (127)
Cancer (1139)
Cardiovascular disease (103)
Career advice (1674)
Cell therapy (252)
Clinical research (66670)
Collaboration (412)
Compensation (205)
COVID-19 (2597)
C-suite (100)
Data (1145)
Diabetes (158)
Diagnostics (6211)
Earnings (86128)
Employer resources (147)
Events (113279)
Executive appointments (316)
FDA (16996)
Funding (371)
Gene therapy (194)
GLP-1 (623)
Government (4432)
Healthcare (19021)
Infectious disease (2682)
Inflammatory bowel disease (116)
Interviews (308)
IPO (16618)
Job creations (3703)
Job search strategy (1430)
Layoffs (444)
Legal (7943)
Lung cancer (179)
Manufacturing (182)
Medical device (13324)
Medtech (13329)
Mergers & acquisitions (19476)
Metabolic disorders (430)
Neuroscience (1571)
NextGen Class of 2024 (6738)
Non-profit (4538)
Northern California (1503)
Obesity (249)
Opinion (201)
Patents (104)
People (57686)
Phase I (20870)
Phase II (29399)
Phase III (21787)
Pipeline (463)
Postmarket research (2622)
Preclinical (8950)
Radiopharmaceuticals (252)
Rare diseases (235)
Real estate (6003)
Regulatory (22070)
Research institute (2414)
Resumes & cover letters (351)
Southern California (1328)
Startups (3753)
United States (13952)
Vaccines (569)
Weight loss (187)
Date
Today (45)
Last 7 days (685)
Last 30 days (3797)
Last 365 days (36889)
2024 (33870)
2023 (41129)
2022 (52433)
2021 (56879)
2020 (55022)
2019 (47520)
2018 (35798)
2017 (33189)
2016 (32486)
2015 (38532)
2014 (32328)
2013 (27245)
2012 (29335)
2011 (29974)
2010 (28150)
Location
Africa (732)
Arizona (201)
Asia (38801)
Australia (6449)
California (3436)
Canada (1303)
China (259)
Colorado (151)
Connecticut (163)
Europe (84763)
Florida (469)
Georgia (116)
Illinois (354)
Indiana (199)
Kansas (99)
Maryland (591)
Massachusetts (2740)
Michigan (160)
Minnesota (280)
New Jersey (976)
New York (982)
North Carolina (761)
Northern California (1503)
Ohio (141)
Pennsylvania (858)
South America (1108)
Southern California (1328)
Texas (482)
Utah (92)
Washington State (376)
703,579 Results for "inhibitor therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
News
Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
October 25, 2024
·
5 min read
Press Releases
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
August 23, 2024
·
3 min read
Business
Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A
Alivexis, Inc. and Melodia Therapeutics AG, a company established by Forty51 Ventures, announced that they have entered into an exclusive license agreement for the worldwide development, manufacturing, and commercialization of Alivexis’ MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential.
June 21, 2024
·
3 min read
Drug Development
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
Ensho Therapeutics, Inc. launched with the announcement that it has acquired a portfolio of oral α4β7 integrin inhibitors through a worldwide exclusive license agreement with EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd.
June 27, 2024
·
9 min read
BioCapital
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
Inhibitor Therapeutics, Inc. has entered into an exclusive, worldwide licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930 “New Angiogenesis Inhibitors”.
December 13, 2023
·
5 min read
Biotech Beach
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
Kura Oncology, Inc. today reported preclinical data supporting the potential therapeutic utility of menin inhibitors in the treatment of diabetes.
June 24, 2024
·
6 min read
Business
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
At the forefront of the Inhibitor Therapeutics, Inc. pipeline is the use of Itraconazole to treat basal cell carcinomas in Basal Cell Carcinoma Nevus Syndrome aka Gorlin Syndrome.
December 19, 2023
·
9 min read
Drug Development
Ensem Therapeutics Announces Achievement of Milestone Following Entry of Small Molecule CDK2 Inhibitor into Clinical Trials for Solid Tumors
Ensem Therapeutics, Inc. today announced that its partner BeiGene has dosed the first five patients in its first-in-human Phase 1 trial to evaluate BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of solid tumors.
June 12, 2024
·
2 min read
Drug Development
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
Aprea Therapeutics, Inc. today announced that the first patient has been dosed in the ACESOT-1051 Phase 1 study evaluating daily oral WEE1 inhibitor APR-1051 as monotherapy in advanced solid tumor patients with unmet medical need.
June 17, 2024
·
7 min read
Pharm Country
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Aprea Therapeutics, Inc. today announced that it will host a virtual KOL event to discuss APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor, on Monday, June 24, 2024 at 9:00 AM ET.
June 21, 2024
·
6 min read
1 of 70,358
Next
